WFH/X
Jul 29, 2025, 13:12
AAV Gene Therapies for Hemophilia A and B: Current Perspectives
The World Federation of Haemophilia (WFH) shared a proud post on X:
“Gene Therapy is transforming Hemophilia care. A new review highlights how AAV-based treatments for hemophilia A and B are delivering long-term results—some lasting years with just one dose. Challenges remain, but the future is promising.
Read more.”
Title: Gene therapy for hemophilia – From basic science to first approvals of “one-and-done” therapies
Authors: Roland W. Herzog, Radoslaw Kaczmarek, Katherine A. High
Stay informed with Hemostasis Today.
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS
-
Apr 14, 2026, 17:00Anna A. Avagyan: Glad to Be Part of EHA Pediatric Hematology-Oncology Course
-
Apr 14, 2026, 16:58Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids
-
Apr 14, 2026, 16:56Saskia Middeldorp: Key Takeaways from the 2026 ACC/AHA Guideline on Acute PE
-
Apr 14, 2026, 16:54Chokri Ben Lamine: Extracorporeal Photopheresis for aGVHD cGVHD Post-SCT – 50 Pearls
-
Apr 14, 2026, 16:49Ahmed Magdi Omar: Key Takeaways From the Latest 2026 Guidelines on Antiplatelet Therapy in AIS